11. The method of claim 1, wherein the B-RAF inhibitor is administered orally. 12. The method of claim 1, wherein the immune checkpoint inhibitor is a PD-1 axis binding antagonist. 13. The method of claim 12, wherein the PD-1 axis binding antagonist is an anti-PD-L1 antibody. 14....
5.The platform system of claim 1, wherein said mounting plate comprises:an under surface configured to be disposed to face the bottom surface of the cooking space; anda plurality of adjustable mounts, each being configured to adjust its respective height so as to collectively adjust a space bet...
4. The method of claim 1, wherein said Raf protein kinase is C-raf. 5. A method of testing for inhibitors of a cellular transformation phenotype induced by an oncogene, wherein the protein encoded by the oncogene functions upstream of a Raf protein kinase in a ras-dependent signal transduc...
6. The compound of claim 1 wherein the compound of formula II is selected from the group consisting of 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate, 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sul...
48. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 26 for use in the treatment of kidney disease. 49. The composition of claim 48, wherein the kidney disease is polycystic kidney disease. 50. A compound selected from Formula III: wherein R20 is hy...
I claim: 1. In a process of manufacturing paper filled with a filler comprising a substantially waterinsoluble carbonate, the steps of bringing into substantially intimate contact materials comprising substantially water-insoluble carbonate and a copper compound selected from a group consisting of copper...
As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include...